Spire Healthcare Group PLC · LSE:SPI

Spire Healthcare — Investor Presentation (April 2011)

31 slides from Spire Healthcare's investor presentation, April 2011

  1. Slide 1: Arthritis in Children

    ARTHIRITIS in CHILDREN Dr. Jeewan Rawal Consultant Paediatrician Spire Hartswood Hospital April 2011

  2. Slide 2: Juvenile Idiopathic Arthritis

    Juvenile Idiopathic Arthritis Case scenario J. I. Arthritis Discussion - Q/A

  3. Slide 3: Case History

    Case History JH Now 12.6 years Boy At 18/12 – Intermittent swelling of right knee following a fall /night pain / limp/early morning stiffness GP → Ortho. Swollen rt knee ; fluid; full range movements; little pain ; walking normally → CIA

  4. Slide 4: Case History

    Case History C . I . Arthritis →Adult Rheumatologist Exam: normal except thick synovium Reactive / post traumatic arthritis Serology negative Physio / Ibuprofen

  5. Slide 5: Case History

    Case History F/ up – wasting of quadriceps ↓ Paed. Rheumatology Synovotis rt knee / mild swelling of lt ankle Oligoarticular JIA (ANA –VE) Admitted for i/a steroid Opthal. Check locally

  6. Slide 6: Case History

    Case History Continued to make good progress / physio and hydro & brufen 3 yrs 9 months - relapse lt. ankle - I/a steroid Leg length difference - podiatrist Continued physio and hydro & brufen 6 yrs – relapse – i/a steroids Continued to make good progress Methotrexate discussed 2005 – 2011 – JIA Qui

  7. Slide 7: Juvenile Idiopathic Arthritis

    Juvenile Idiopathic Arthritis Heterogeneous < 16 years Persist for more than six weeks Multi-factorial autoimmune disease Environmental and genetic contributory factors Most common risk factors are infections? Stress and maternal smoking Multiple genes involved Incidence: 0.07-4.01 per 1000 Exists w

  8. Slide 8: Diagnosis / History?

    Diagnosis / History ? No conclusive laboratory tests Good history and physical examination History: morning stiffness > 15 min improves during the day Problems with, walking, running, climbing stairs, standing up, writing, or sleeping. Need help with daily activities Autoimmune disease in relatives

  9. Slide 9: Diagnosis / Examination?

    Diagnosis / Examination? Examine all joints Pain or tenderness, swelling, limited movement < strength or muscle atrophy Bony deformity Observe walking, standing up, sitting down, or climbing on table. Lymphadenopathy, organ enlargement, systemic rashes, nail abnormalities, psoriatic rash, or enthesi

  10. Slide 10: Clinical Features

    Clinical Features embhees i tise: bate got her atis a = Gefo-ferss ene He murt hor itis: 0 pseoriasisarchrisis lox Sysberncs& 14. | noly AF -positiv 4% olipo-fabended 1S poly-A.F-negativ 1% Bigs. 1. fewer! tadtopatts® artistic, Fordeling af subtyper

  11. Slide 11: Clinical features Systemic JIA

    Clinical features Systemic JIA Categories Characteristi % of total Onset age Sex ratio Relative cs (F:M) risk (European v non- European Systemic Arthritis and Throughout juvenile daily fever ≥3 4-17 1:1 2.5 days, +one: childhood idiopathic non-fixed arthritis erythematous rash, generalised lymph nod

  12. Slide 12: Systemic JIA

    Systemic J I A

  13. Slide 13: Oligoarthritis JIA

    Oligoarthritis JIA Categories Characteristics % of total Onset age Sex ratio Relative risk (F:M) (European v non- European Oligoarthritis Arthritis Early affecting 1-4 27-60 childhood 5:1 joints during (peak 2-4 the first 6 years) months of disease Persistent Arthritis affecting ≤4 joints 40 3.3 thr

  14. Slide 14: Oligoarthritis

    Oligoarthritis

  15. Slide 15: Polyarthritis JIA

    Polyarthritis JIA Categories Characteristics % of total Onset age Sex ratio Relative risk (F:M) (European v non- European Polyarthritis: Arthritis affecting ≥5 joints during the first 6 months of disease Rheumatoid Two or more Late factor positive tests for 2-7 childhood or 3:1 0.8 rheumatoid factor

  16. Slide 16: Polyarthritis

    Polvarthritis: Handa of a child with averse idiopathic arthwitis

  17. Slide 17: Psoriatic / Enthesitis JIA

    Psoriatic / Enthesitis JIA Categories Characteristics % of total Onset age Sex ratio Relative risk (F:M) (European v non- European Arthritis and Psoriatic Late arthritis psoriasis, or arthritis and at least 2 of the 2-11 childhood or 1:0.95 6.4 following: dactylitis, nail pitting or onycholysis, pso

  18. Slide 18: Clinical features

    Clinical features Oligoarthritis usually knees, ankles, or elbows Chronic anterior uveitis 20% polyarthritis symmetrical arthritis in large and small joints uveitis less common Systemic fever at least three days. arthritis, which affects a variable number of joints, weeks or even years after systemi

  19. Slide 19: Differential diagnosis

    Differential diagnosis Arthritis Infective and reactive; Connective tissues disorders; SLE Systemic vasculitis: HSP Other: inflammatory bowel disease; haemophilia Mechanical and degenerative causes Trauma Hyper mobility Avascular necrosis Perthes’ disease, Osgood-Schlatter’s disease, Scheuermann’s d

  20. Slide 20: Differential diagnosis

    Differential diagnosis Non-organic causes LIPS / DIPS Benign nocturnal idiopathic limb pains (growing pain) Psychogenic: Miscellaneous: Osteomyelitis; rickets, tumours Genetic disorders: collagen disorders - Ehlers-Danlos syndrome,

  21. Slide 21: Investigations

    Investigations Full blood examination, Inflammatory markers (ESR, CRP), Autoimmune markers (Rheumatoid factor, HLA B27, and Antinuclear antibodies) Imaging studies - narrowing of the joint spaces or erosions MRIstudies inflamed synovium and increased joint fluid.

  22. Slide 22: Sequelae?

    Sequelae ? Persistent oligoarthritis – mildest form Systemic - most severe form Pain, fatigue, and limitation in daily activities Uveitis, 5-20% of patients, cataracts , blindness Amyloidosis and macrophage activation syndrome. Flexion deformities, damage of cartilage and bone Bony overgrowth - limb

  23. Slide 23: Sequelae?

    Sequelae ? Large proportion - enter adulthood with active disease. low health related quality of life physical, emotional, and social wellbeing. lower self esteem, behavioural problems limited social lives patient’s family is also affected family cohesion is not affected

  24. Slide 24: Slide 24

  25. Slide 25: Management

    Management Refer - paediatric rheumatology clinic ASAP Time to treatment is ∞ response to treatment. Aims: Achieve remission Improve life quality More aggressive treatment approach Early introduction of DMARD Prevents or minimises long term sequelae Multidisciplinary Core set of response variables

  26. Slide 26: Core set of response variables

    Core set of response variables Global assessment of the disease activity by the doctor using a visual analogue scale (VAS) (range 0-100 mm, 0 best score) Childhood health assessment questionnaire (CHAQ) (range 0-3, 0 best score) used by the patient or parent (measures functional ability) Global asse

  27. Slide 27: Management

    Management Juvenile idiopathic arthritis | I f | t Oligoarticular disease Polyarnticular disease Systemic disease HSAIDS — HS4Al Os HSA) 0S a al af oe - ~ Conese +/> Donic 4 of LAS = f= LASS o LAS Synthetic DMARDs Synthetic DAAR Ds . + sf ~ I : Confetti + if +/- Dondicosierods le i aj LAS. +/'= DS +

  28. Slide 28: Management

    Management NSAIDs None superior Newer cyclo-oxygenase-2 inhibitors -no more effective or safer / Naproxen I/A corticosteroids Triamcinolone hexacetonide is superior systemic corticosteroids while waiting for DMARDs to take effect unresponsive to treatment with DMARDs.

  29. Slide 29: DMARDs

    DMARDs Synthetic Methotrexate Sulfasalazine leflunomide ciclosporin A Biological Anti-TNF - etanercept, adalimumab, infliximab Anti- interleukin 1/6 – anakinra / tocilizumab Anti – T / B cells – abatacept / rituximab

  30. Slide 30: Take Home Message?

    Take Home Message? Early recognition Early aggressive treatment Paediatric Rheumatology multidisciplinary Goal – early remission – DMARDs More data for long term effect - DMARDs Avoid live vaccine while on DMARDs C. Pox immune status before - DMARDs

  31. Slide 31: Thank you

Spire Healthcare Group — Investor Presentation (April 2011) on 6ix